Dr. Yu Zhang conducted postdoctoral training at Harvard Medical School/Boston Children’s Hospital from 2005 to 2012. From 2013 to 2022, he served as  an assistant Investigator at the National Institute of Biological Sciences, Beijing (NIBS, Beijing). In 2023, he joined the Chinese Institutes for Medical Research, Beijing (CIMR) as an associate Investigator. Dr. Zhang has published studies in major journals such as Cell, Circulation, Cell Research, Genome Biology, Nature Communications, and PNAS, among others. His papers have been referenced more than 6700 times, and he has an H-index of 29. His research group focuses on developing and utilizing functional genomics screening, multi-omics high-throughput sequencing technologies, and bioinformatics analysis. By combining in vivo and in vitro mouse models with human tumor models, they investigate the regulatory mechanisms of key molecules in tumor immunity. Dr. Zhang’s team aims to develop new methods for tumor immunotherapy and translate research findings into clinical applications.